ZEMDRI Drug Patent Profile

When do Zemdri patents expire, and what generic alternatives are available?

Zemdri is a drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this compound. Additional details are available on the plazomicin sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zemdri

Zemdri was eligible for patent challenges on June 25, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 25, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZEMDRI

International Patents:	28
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEMDRI

US Patents and Regulatory Information for ZEMDRI

ZEMDRI is protected by four US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes				Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes			Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes				Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes

International Patents for ZEMDRI

When does loss-of-exclusivity occur for ZEMDRI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEMDRI around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	200927146	Antibacterial aminoglycoside analogs
Brazil	PI0819319
Croatia	P20170154
Japan	2011504508
Portugal	2217610
Mexico	2010005632	ANALOGOS DE AMINOGLUCOSIDOS ANTIBACTERIANOS. (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS.)
Poland	2217610

ZEMDRI Market Analysis and Financial Projection

Last updated: April 23, 2026

ZEMDRI (Zanubrutinib) Investment Scenario and Fundamentals Analysis

ZEMDRI is a branded oncology therapy centered on BTK inhibition. The investment case is driven by (1) labeled market opportunity tied to the specific approved indications, (2) competitive intensity in BTK inhibitor class and adjacent pathways, and (3) durability of revenue from dosing convenience, safety/tolerability profile, and line-of-therapy positioning. Core fundamentals hinge on adoption against incumbents, persistence, and incremental label expansion.

What is ZEMDRI and what does it treat?

ZEMDRI is zanubrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene (now BeiGene/Suzhou-Hengrui transaction structure is not required here). It is used in oncology settings where BTK inhibition underpins B-cell malignancy control. The investment-relevant point is that ZEMDRI competes inside a mature BTK class with established prescribing inertia and switching costs.

Investment implication: The near-term revenue ceiling depends on whether ZEMDRI sustains share gains in its labeled niches versus losing share to cheaper generics (where applicable), follow-on BTK inhibitors with stronger safety positioning, and alternative regimens (BCL2, anti-CD20, CAR-T, bispecifics).

What is the regulatory and commercial status that matters to investors?

For investment underwriting, the key inputs are (a) approved indications and their sequencing, (b) label breadth, and (c) geography because BTK class uptake differs by reimbursement mechanics and treatment guidelines. ZEMDRI’s commercial trajectory is shaped by how quickly physicians move from established BTK incumbents to zanubrutinib-based regimens.

Investment implication: A branded BTK entrant’s performance depends on whether it captures treatment-naïve and later-line patients at meaningful share, or only earns incremental pull-through in subgroups.

---

How large is the addressable market and where is the revenue likely to come from?

Which patient populations typically drive BTK revenue?

BTK inhibitors generally derive revenue from a mix of:

• Relapsed/refractory (R/R) settings where BTK is standard-of-care or a preferred option.
• Treatment-naïve niches when BTK is incorporated into frontline regimens.
• Subgroup-driven adoption where tolerability, comorbidity profiles, or fixed dosing schedules shift prescribing.

Investment implication: If ZEMDRI’s label is concentrated in R/R lines, growth is capped by competitive switching and subsequent-line displacement by bispecifics, CAR-T, and venetoclax-based approaches. If it has credible frontline or broader expansion, growth can be more durable.

Where can incremental growth realistically come from?

Revenue growth for ZEMDRI typically comes from four levers:

• Share shift within BTK inhibitor prescribing (switching from acalabrutinib or ibrutinib).
• Line-of-therapy expansion (moving earlier in the care pathway).
• Combination uptake if guidelines adopt zanubrutinib in combination regimens.
• Geography expansion where reimbursement and formularies mature.

Investment implication: The strongest near-term growth case is a sustained share shift combined with line-of-therapy pull, not one-time label events.

---

How does ZEMDRI stack up against BTK competitors on fundamentals?

Who are the direct competitive benchmarks?

ZEMDRI competes in the BTK inhibitor class against:

• ibrutinib
• acalabrutinib
• (and, by therapeutic proximity, other B-cell therapies that can displace BTK use)

Investment implication: BTK class competition is not only efficacy. It is also dosing schedule, bleeding/atrial fibrillation risk profiles, drug-drug interaction burden, and supportive evidence in guideline-endorsed settings.

What is the class-level adoption pattern investors should assume?

Physicians often maintain patients on a BTK once started if safety is acceptable, then switch at clear clinical inflection points. That pattern favors:

• therapies with consistent tolerability,
• therapies that are easy to integrate with anticoagulation and other comedications,
• and therapies backed by strong comparative and durability evidence.

Investment implication: ZEMDRI’s growth rate depends on whether it reduces switching friction versus incumbents and whether safety signals are convincing enough to overcome inertia.

---

What does the efficacy and safety profile imply for sales durability?

Why safety and tolerability matter for BTK economics

BTK inhibitor economics depend on:

• Treatment persistence (time-on-drug is revenue).
• Dose reductions and discontinuations (affect effective utilization).
• Adverse event management costs (supportive care, monitoring).
• Physician willingness to start (frontline adoption depends on perceived risk).

Investment implication: A favorable balance of tolerability supports longer persistence and higher start rates, especially in older or comorbid populations that dominate the BTK treatable incidence.

How to translate clinical profile into investor-readable metrics

Even without modeling proprietary data, investors should watch:

• prescription-to-persistence (how many patients remain on therapy beyond expected intervals),
• discontinuation reasons and rates,
• dosing pattern stability,
• and uptake speed after guideline updates.

Investment implication: If ZEMDRI shows persistent real-world continuation above class average, that supports a durable revenue base even in slower patient growth scenarios.

---

Investment scenario: base, bull, and bear

Base case

Assumption set: ZEMDRI captures incremental share within its labeled niches without materially displacing incumbents elsewhere, with steady adoption and normal persistence.

Revenue dynamics:

• Growth tracks market expansion plus modest share shift.
• Competition limits acceleration beyond label boundaries.
• Line-of-therapy mix remains stable.

Valuation driver: Market share gain per quarter and persistence durability.

Bull case

Assumption set: ZEMDRI gains share faster than expected due to guideline adoption, favorable real-world tolerability, and stronger-than-expected combination uptake.

Revenue dynamics:

• Frontline or broader label uptake increases.
• Persistence remains high, reducing churn.
• Physicians switch earlier in R/R sequencing.

Valuation driver: Faster-than-class adoption curve plus incremental label breadth.

Bear case

Assumption set: Competitive pressure intensifies, pricing pressure emerges, and alternatives (bispecifics/CAR-T/venetoclax-based regimens) reduce BTK share.

Revenue dynamics:

• Share gains stall.
• Persistence deteriorates due to tolerability in subgroups or higher discontinuation.
• Clinicians defer BTK in favor of newer modalities.

Valuation driver: Evidence of share erosion and reduced persistence.

---

What market and pricing factors can change the outcome fast?

Pricing power and reimbursement

BTK inhibitors face market-level pricing sensitivity. ZEMDRI’s commercial outcome depends on:

• formulary inclusion,
• step-therapy rules,
• rebates and payer contracting,
• and net price versus list price.

Investment implication: A branded drug can lose revenue even while maintaining prescriptions if payer terms worsen.

Guidelines and treatment sequencing

If society guidelines position BTK later in therapy, ZEMDRI’s growth slows. If they move BTK earlier or recommend zanubrutinib-based regimens, growth accelerates.

Investment implication: Guideline changes often drive step-function shifts in adoption.

---

Operational and strategic fundamentals that matter

Portfolio alignment and pipeline optionality

ZEMDRI’s value is partially a function of:

• BeiGene pipeline depth in adjacent hematologic malignancies,
• ability to secure combination regimens,
• and tempo of label expansions.

Investment implication: Pipeline credibility affects payer and physician trust, accelerating or delaying adoption.

Manufacturing and supply reliability

BTK economics also depend on:

• uninterrupted supply,
• batch consistency,
• and minimal treatment interruption risk.

Investment implication: Reliability issues can harm persistence metrics quickly.

---

Key takeaways

• ZEMDRI is a BTK inhibitor where revenue durability depends on persistence, payer access, and whether zanubrutinib expands beyond limited labeled niches.
• The investment case is mostly a share and sequencing story: speed of adoption versus acalabrutinib and ibrutinib incumbency, plus guideline-driven line-of-therapy positioning.
• The bull case requires early and sustained share gains with high persistence; the bear case is fueled by sequencing displacement by newer modalities and payer-driven net price compression.
• For underwriting, the most predictive real-world fundamentals are start rate, persistence, discontinuation drivers, and net pricing versus competitors.

---

FAQs

1. Is ZEMDRI’s investment profile more sensitive to new patient starts or persistence?
   Persistence is usually the higher-signal metric for BTK economics because time-on-drug directly converts to revenue and reduces churn-driven volatility.

2. What competitor behaviors most threaten ZEMDRI share?
   Aggressive payer contracting by incumbents, guideline-aligned sequencing advantages, and clinically differentiated safety narratives that reduce switching.

3. What market events would most change ZEMDRI’s outlook quickly?
   Label expansions, guideline updates that shift line-of-therapy, and payer formulary changes that alter access or net price.

4. How should investors monitor ZEMDRI’s real-world adoption?
   Prescription growth rate relative to class, persistence curves, discontinuation reasons, and region-by-region reimbursement access.

5. What is the biggest bull-case lever for ZEMDRI?
   Combination or broader label uptake that pulls zanubrutinib earlier into therapy while maintaining persistence through tolerability management.

---

References (APA)

[1] FDA. (n.d.). Drug trials snapshots: Zanubrutinib. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots
[2] European Medicines Agency. (n.d.). Brukinsa (zanubrutinib) product information. European Medicines Agency. https://www.ema.europa.eu
[3] National Comprehensive Cancer Network. (n.d.). NCCN Guidelines: B-Cell Lymphomas and relevant hematologic malignancies. NCCN. https://www.nccn.org